<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04415658</url>
  </required_header>
  <id_info>
    <org_study_id>ODRC-002</org_study_id>
    <nct_id>NCT04415658</nct_id>
  </id_info>
  <brief_title>Intravenous Thyroxine for Heart-Eligible Organ Donors</brief_title>
  <official_title>A Multicenter Randomized Placebo-Controlled Trial of Intravenous Thyroxine for Heart-Eligible Brain Dead Organ Donors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Mid-America Transplant</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized controlled trial will evaluate whether intravenous thyroxine infusion given
      to brain-dead organ donors who are eligible to donate hearts for 12 hours will result in more
      hearts transplanted than saline placebo
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background: Brain death frequently induces hemodynamic instability and cardiac stunning.
      Impairments in cardiac performance are major contributors to hearts from otherwise eligible
      organ donors not being transplanted. Deficiencies in pituitary hormones (including thyroid
      stimulating hormone) may contribute to hemodynamic instability and replacement of thyroid
      hormone has been proposed as a means of improving stability and increasing hearts available
      for transplantation. Intravenous thyroxine is commonly used in donor management. However,
      small controlled trials have not been able to demonstrate efficacy.

      Methods: This multicenter study will involve organ procurement organizations (OPOs) across
      the country. A total of 800 heart-eligible brain dead organ donors who require vasopressor
      support will be randomly assigned to intravenous thyroxine for at least 12-hours or saline
      placebo. The primary study hypothesis is that thyroxine treatment results in more hearts
      transplanted. Additional outcome measures are time to achieve hemodynamic stability (weaning
      off vasopressors) and improvement in cardiac ejection fraction on echocardiography.

      Discussion: This will be the largest randomized controlled study to evaluate the efficacy of
      thyroid hormone treatment for organ donor management. By collaborating across multiple OPOs,
      it will be able to enroll an adequate number of donors and be powered to definitively answer
      the critical question of whether treatment increases hearts transplanted and/or provides
      other hemodynamic benefits.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 29, 2020</start_date>
  <completion_date type="Anticipated">April 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Heart transplanted</measure>
    <time_frame>One week</time_frame>
    <description>Whether heart is transplanted into living recipient</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time till off vasopressors</measure>
    <time_frame>72 hours</time_frame>
    <description>Time in hours from randomization to when weaned off vasopressors (except vasopressin)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weaned off vasopressors</measure>
    <time_frame>12 hours</time_frame>
    <description>Weaned off vasopressors within twelve hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to order echo</measure>
    <time_frame>72 hours</time_frame>
    <description>Time till hemodynamic stability permits ordering initial echocardiogram</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ejection fraction</measure>
    <time_frame>72 hours</time_frame>
    <description>Left ventricular ejection fraction measured on first echocardiography</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Total organs transplanted</measure>
    <time_frame>One week</time_frame>
    <description>Total number of organs transplanted</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">800</enrollment>
  <condition>Brain Death</condition>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Thyroxine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravenous thyroxine infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Intravenous saline infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thyroxine</intervention_name>
    <description>Infusion prepared by mixing 500 μg of drug in 500-ml of normal saline (i.e. concentration of 1 μg/ml) and enclosing the bag in an opaque sleeve. Infusion started at 30 μg/hour (30 ml/hour) for twelve hours.</description>
    <arm_group_label>Thyroxine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>The placebo will be a 500-ml bag of normal saline (without active drug) also enclosed in an opaque sleeve. This infusion will also be started at 30 ml/hour for twelve hours.</description>
    <arm_group_label>Saline Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Declared dead by neurologic criteria (brain dead)

          -  Authorization for organ donation and research

          -  On one or more vasopressors and/or inotropes

        Exclusion Criteria:

          -  Brain death declared more than 24 hours prior

          -  Only vasopressor is vasopressin

          -  Known coronary artery disease or history of myocardial infarction

          -  Known valvular heart disease

          -  Prior sternotomy or cardiac surgery

          -  Donor at VA hospital

          -  Received intravenous or oral thyroxine within past month

          -  Other reason donor is unable to receive study drug (determined by on-site personnel)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rajat Dhar, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gary Marklin, MD</last_name>
    <phone>314-735-8291</phone>
    <email>gmarklin@midamericatransplant.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hannah Mueller</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Mid-America Transplant Services</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gary Marklin, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Dhar R, Stahlschmidt E, Yan Y, Marklin G. A randomized trial comparing triiodothyronine (T3) with thyroxine (T4) for hemodynamically unstable brain-dead organ donors. Clin Transplant. 2019 Mar;33(3):e13486. doi: 10.1111/ctr.13486. Epub 2019 Feb 12.</citation>
    <PMID>30689222</PMID>
  </reference>
  <reference>
    <citation>Dhar R, Stahlschmidt E, Marklin G. A Randomized Trial of Intravenous Thyroxine for Brain-Dead Organ Donors With Impaired Cardiac Function. Prog Transplant. 2020 Mar;30(1):48-55. doi: 10.1177/1526924819893295. Epub 2019 Dec 5.</citation>
    <PMID>31802716</PMID>
  </reference>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>May 27, 2020</study_first_submitted>
  <study_first_submitted_qc>May 29, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 4, 2020</study_first_posted>
  <last_update_submitted>July 16, 2020</last_update_submitted>
  <last_update_submitted_qc>July 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Washington University School of Medicine</investigator_affiliation>
    <investigator_full_name>Raj Dhar</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Organ donor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Death</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol: Appendix (Data Forms)</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>June 23, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/58/NCT04415658/Prot_001.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol: Main Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>July 16, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/58/NCT04415658/Prot_002.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

